Unprotected versus protected high-risk percutaneous coronary intervention with the Impella 2.5 in patients with multivessel disease and severely reduced left ventricular function.

Cardiovascular mortality was numerically higher in the protected PCI group but did not reach statistical significance (22.2% vs 9.1%, P = .28).

also in 111,027 other papers

[ 11 – 13 ] The PROTECT-I trial demonstrated the feasibility and safety of the protected PCI approach with the Impella 2.5 device, while the PROTECT-II trial showed superior hemodynamic support and a strong trend toward lower rates of major adverse cardiac and cerebrovascular events (MACCE) at 3-month follow-up compared to the intraaortic balloon pump.

also in 5,725 other papers

[ 12 – 14 , 25 – 27 ] Compared to intraaortic balloon pump, protected PCI with the Impella showed a trend toward lower MACCE after 90 days while there was no difference after 30 days.

also in 53,322 other papers